Vectans Pharma and SciClone Pharmaceuticals are pleased to announced that China’s National Medical Products Administration (NMPA) has granted the approval of commercialization for the Miconazole Muco-adhesive Buccal Tablet, Oravig®, for the topical treatment of oropharyngeal candidiasis of adult human. Oravig® has already been approved for commercialization in several overseas countries.